Adheip Mally
About Adheip Mally
Adheip Mally is an Equity Research Analyst specializing in Biotechnology, currently employed at Piper Sandler since 2021. He has previously held positions at Guidepoint, H.C. Wainwright & Co., and Maxim Group, and holds a Master of Science from Georgetown University.
Current Role at Piper Sandler
Adheip Mally serves as an Equity Research Analyst in the Biotechnology sector at Piper Sandler. He has held this position since 2021, contributing to the firm's research efforts in the biotechnology industry. His role involves analyzing market trends, evaluating company performance, and providing insights to support investment decisions.
Previous Experience in Equity Research
Prior to his current role, Adheip Mally worked at Maxim Group as an Equity Research Associate specializing in Biotechnology from 2019 to 2021. Before that, he was an Equity Research Associate focused on Specialty Pharmaceuticals at H.C. Wainwright & Co., LLC for three months in 2018. His career began at Guidepoint, where he served as a Research Project Manager in Healthcare from 2017 to 2018.
Education and Expertise
Adheip Mally holds a Master of Science (M.S.) degree in Physiology and Biophysics from Georgetown University, where he studied from 2014 to 2015. He also earned a Bachelor of Science (B.S.) degree in Molecular, Cellular and Developmental Biology from the University of Washington, completing his studies from 2008 to 2012. His educational background provides a strong foundation for his work in biotechnology research.
Academic Background
Adheip Mally completed his secondary education at Bellevue Senior High School. His academic journey continued at the University of Washington, where he obtained a Bachelor of Science degree. He further advanced his studies at Georgetown University, achieving a Master of Science degree, which has contributed to his expertise in the field of biotechnology.